Whether, when, how, and how much? General public's and cancer patients' views about the disclosure of genomic secondary findings.

ABSTRACT:

Background

Data on the modalities of disclosing genomic secondary findings (SFs) remain scarce. We explore cancer patients' and the general public's perspectives about disclosing genomic SFs and the modalities of such disclosure.

Methods

Sixty-one cancer patients (n = 29) and members of the public (n = 32) participated in eight focus groups in Montreal and Quebec City, Canada. They were asked to provide their perspectives of five fictitious vignettes related to medically actionable and non-actionable SFs. Two researchers used a codification framework to conduct a thematic content analysis of the group discussion transcripts.

Results

Cancer patients and members of the public were open to receive genomic SFs, considering their potential clinical and personal utility. Th

SUBMITTER: Cleophat JE 

PROVIDER: S-EPMC8236159 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature